Current therapeutic approach to hypertrophic scars by Bukvić Mokos, Zrinka et al.
June 2017 | Volume 4 | Article 831
Review
published: 20 June 2017
doi: 10.3389/fmed.2017.00083
Frontiers in Medicine | www.frontiersin.org
Edited by: 
Gregor Jemec, 
University of Copenhagen, 
Denmark
Reviewed by: 
Cristina Has, 
Albert Ludwig University 
of Freiburg, Germany  
Elisabetta Palazzo, 
Universita’ di Modena, Italy
*Correspondence:
Zrinka Bukvic´ Mokos  
zrinka.bukvic@zg.t-com.hr
Specialty section: 
This article was submitted 
to Dermatology, 
a section of the journal 
Frontiers in Medicine
Received: 17 March 2017
Accepted: 06 June 2017
Published: 20 June 2017
Citation: 
Mokos ZB, Jovic´ A, Grgurevic´ L, 
Dumic´-Cˇule I, Kostovic´ K, Cˇeovic´ R 
and Marinovic´ B (2017) Current 
Therapeutic Approach to 
Hypertrophic Scars. 
Front. Med. 4:83. 
doi: 10.3389/fmed.2017.00083
Current Therapeutic Approach  
to Hypertrophic Scars
Zrinka Bukvic´ Mokos1*, Anamaria Jovic´1, Lovorka Grgurevic´2, Ivo Dumic´-Cˇule2,  
Krešimir Kostovic´ 1, Romana Cˇeovic´1 and Branka Marinovic´1
1 Department of Dermatology and Venereology, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, 
Zagreb, Croatia, 2 Laboratory for Mineralized Tissues, School of Medicine, University of Zagreb, Zagreb, Croatia
Abnormal scarring and its accompanying esthetic, functional, and psychological sequelae 
still pose significant challe nges. To date, there is no satisfactory prevention or treatment 
option for hypertrophic scars (HSs), which is mostly due to not completely comprehend-
ing the mechanisms underlying their formation. That is why the apprehension of regular 
and controlled physiological processes of scar formation is of utmost importance when 
facing hypertrophic scarring, its pathophysiology, prevention, and therapeutic approach. 
When treating HSs and choosing the best treatment and prevention modality, physicians 
can choose from a plethora of therapeutic options and many commercially available 
products, among which currently there is no efficient option that can successfully 
overcome impaired skin healing. This article reviews current therapeutic approach and 
emerging therapeutic strategies for the management of HSs, which should be individ-
ualized, based on an evaluation of the scar itself, patients’ expectations, and practical, 
evidence-based guidelines. Clinicians are encouraged to combine various prevention 
and treatment modalities where combination therapy that includes steroid injections, 
5-fluorouracil, and pulsed-dye laser seems to be the most effective. On the other hand, 
the current therapeutic options are usually empirical and their results are unreliable and 
unpredictable. Therefore, there is an unmet need for an effective, targeted therapy and 
prevention, which would be based on an action or a modulation of a particular factor 
with clarified mechanism of action that has a beneficial effect on wound healing. As 
the extracellular matrix has a crucial role in cellular and extracellular events that lead to 
pathological scarring, targeting its components mostly by regulating bone morphoge-
netic proteins may throw up new therapeutic approach for reduction or prevention of 
HSs with functionally and cosmetically acceptable outcome.
Keywords: wound healing, skin scarring, hypertrophic scar, scar management, topical therapy, prevention, 
treatment
iNTRODUCTiON
Skin is the largest organ in the human body that is in constant contact with the environment with 
its primary role to adapt to stresses and tension and to protect other systems within the body. When 
injured, it must rapidly repair itself to maintain the cutaneous integrity and its external defense 
function. As a response to injury, at the site of tissue disruption, the highly organized process of 
wound healing instantly begins and ultimately results in the formation of a scar that never obtains 
the flexibility or the strength of the original tissue (1). The fact that in the developed countries about 
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100 million people per year form a dermal scar as a consequence 
of elective operations or injuries puts this problem among the 
most common in modern medicine and represents a huge cost 
to each health system (2, 3). We can expect around 30% of these 
to undergo abnormal growth due to aberrations in physiologic 
healing that result in hypertrophic scar (HS) or keloid formation, 
which are frequently accompanied by a number of esthetic, func-
tional, and social impairments and may lead to decreased quality 
of life (4). Normotrophic, atrophic, hypertrophic, and keloid scars 
are all various types of scars with its different clinical appearance, 
etiology, and pathogenesis, demanding different therapeutic 
approach. The apprehension of regular and controlled physiologi-
cal processes of scar formation is of the utmost importance when 
facing hypertrophic scarring, its pathophysiology, prevention, 
and therapeutic approach.
MeTHODOLOGY
In preparing this work, we used PubMed, Google Scholar, and 
Web of Science to perform literature searches on HS-related 
research. Key terms used in the search were “scarring,” “wound 
healing,” “hypertrophic scar,” “scar management,” “scar preven-
tion,” and “scar treatment.” Review articles were used as an initial 
source of information and, where relevant, information from 
primary research papers was obtained.
wOUND HeALiNG AND SCAR 
FORMATiON
When it comes to deep skin damage, the wound heals in a highly 
regulated series of dynamic and physiological processes involv-
ing various cells, matrix molecules, cytokines, and mediators 
(5). Wound healing is divided into continuous and overlapping 
phases including coagulation, inflammatory response phase (the 
first 48–72 h after the injury); proliferation phase that includes 
the formation of extracellular matrix (ECM), angiogenesis, and 
re-epithelization (days 4–21); and final remodeling or maturation 
phase, which may last up to a year (6, 7). This final regeneration 
phase results in the formation of a scar with excess collagen and an 
absence of cutaneous fat and hair follicles (1). Fibrillar collagen, 
as a main structural component of the ECM, has a crucial role 
both for the elasticity and the strength of an intact skin and scar 
tissue (8). Both normal and pathological scars are the result of 
deposition of collagen type I and III, although collagen synthesis 
in HSs is two to three times as much as in normotrophic scars 
(9). Collagen III increases more than type I in the early stages of 
wound healing but decreases during maturation phase to normal 
levels (10).
THe CRiTiCAL ROLe OF 
MYOFiBROBLASTS AND  
OTHeR eCM COMPONeNTS
It is suggested today that it is the ECM that has the critical 
role in the scar formation (7). Major players involved in the 
ECM production are fibroblasts, myofibroblasts, transforming 
growth factor-beta (TGF-β), proteoglycans—decorin, laminin, 
and fibronectin, matrix metalloproteinases (MMPs), and bone 
morphogenetic proteins (BMPs) (7). A key role in the formation 
of dense collagen matrix during the maturation phase belongs to 
myofibroblasts originating from fibroblasts, which disappear by 
apoptosis during normal wound healing when epithelialization 
occurs (11–13). Various biological properties of both fibroblasts 
and myofibroblasts have profound impact on the progression 
and regression of HS. These complex processes are influenced 
by a signaling network involving different cytokines and growth 
factors of which are to mention, TGF-β, epidermal growth fac-
tor, platelet-derived growth factor, connective tissue growth 
factor (CTGF), and vascular endothelial growth factor, which is 
known as a key factor in angiogenesis essential for wound healing 
(14, 15). The transition from fibroblasts to myofibroblasts express-
ing α-smooth muscle actin (SMA) is influenced by cytokines, 
previously listed growth factors, especially TGF-β whose activity 
diminishes upon the completion of wound repair, mechanical 
stress, and cellular fibronectin (16). Myofibroblasts are responsi-
ble for the production of type I and III collagen, secretion of profi-
brotic cytokines, remodeling of an immature ECM, and wound 
contraction (12, 16, 17). Additionally, they produce MMPs that 
catalyze the hydrolysis of the main components of ECM as well as 
the activity of cytokines and growth factors (18, 19). Degradation 
of fibrillar collagen type I, II, and III is mediated by specific col-
lagenases-1, 2, and 3 (MMP-1, 8, and 13) and gelatinases MMP-2 
and MMP-9 (18). MMPs transcription is not only induced by 
glucocorticosteroids and interleukin (IL)-1 but also regulated by 
TGF-β and insulin-like growth factor-1 (20, 21). MMPs expres-
sion is low in intact skin, but after injuring their expression is 
increased (19). It has been demonstrated that inhibitors of MMPs 
slow wound healing in vivo, which indicates that the MMPs are 
the key regulators of many wound healing processes (19, 22). 
One of the most important MMPs for the formation of fibrous 
tissue is procollagen C proteinase-1, BMP1, of the BMP family, 
which cleaves the carboxylic pro-domain of procollagen I, II, and 
III to form the insoluble fibrillar collagen of exceptional tensile 
strength (23–25). Although isolated with other BMP molecules 
due to their affinity for the heparin, BMP1 does not share the 
same amino acid sequence homology with other BMPs so it is 
not an authentic member of the TGF-β superfamily. It belongs 
to the astacin/BMP1/tolloid-like family of zinc MMPs that are 
fundamental in the development and formation of the ECM 
(23, 26). The importance of BMP1 protein was stressed two 
decades ago by finding that Bmp1−/− mice die shortly after birth 
from the failure of ventral body wall closure due to abnormal 
collagen fibrillogenesis (27). To overcome issues of early lethality 
and functional redundancy in Bmp1−/− mice, Muir et  al. (28) 
recently utilized BTKO mice with floxed Bmp1 and Tll1 alleles and 
they came to the findings that loss of the BMP1 proteinase activ-
ity resulted in delayed wound healing and significantly thinned 
and fragile skin with unusually densely grouped collagen fibrils. 
Their experiment confirmed BMP1-like proteinases as essential 
proteins to the structure and wound healing of the skin. BMP1 
proteinases are crucial for the formation of ECM not only by 
direct influence to its formation but also indirectly by activat-
ing TGF-β superfamily members including BMP-2 and BMP-4, 
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profibrotic TGF-β1, and growth and differentiation factors GDF-
8/-11 and IGF (24, 26). To date, there are seven different isoforms 
of the BMP1 protein (25). A substantial progress in the field 
of fibrotic diseases in human has been made by findings of a 
number of BMP1 isoforms at the protein level in the circulation 
of patients with a variety of fibrotic conditions such as chronic 
kidney disease, acute bone fracture, acute myocardial infarction, 
but most importantly BMP1-3 isoform known as mammalian 
tolloid that circulates as an active enzyme in plasma samples of 
healthy individuals in lower concentrations (29, 30). Grgurevic 
et al. (29) utilized their findings of BMP1-3 protein and tested 
its effect in rats with chronic kidney disease where administra-
tion of rhBMP1-3 increased fibrosis, while BMP1-3 neutralizing 
antibody reduced it and was associated with low plasma levels of 
TGF-β1, CTGF, and decreased expression of decorin, suggesting 
that this pathway may be therapeutic target for fibrosis. Decorin 
is a small leucine-rich proteoglycan produced by myofibroblasts 
that regulates collagen fibrillogenesis, inhibits the proliferation 
of fibroblasts, and reduces production of TGF-β1 and collagen 
synthesis in HS fibroblasts whose production is here significantly 
increased (31–33). Another important proteoglycan that is pro-
duced by myofibroblasts, as well as by keratinocytes, endothelial 
cells, and dermal fibroblasts is cellular fibronectin. It is respon-
sible for the formation of stable collagen I/III fibrillar network 
through a mechanism involving integrins (34) but it is also vital 
for regulating the neovascularization of granulation tissue (35).
Most recently, a breakthrough study that identifies another 
consequential role of myofibroblast was published (36). Although 
it has been thought that they are differentiated, this study showed 
that adipocytes may be regenerated from myofibroblasts during 
wound healing through activation of adipocyte transcription 
factors expressed during development, triggered by crucial BMP 
signaling from the actively growing hair follicles. These findings 
fortify the importance of BMPs during wound healing and scar 
formation and identify the myofibroblasts as a plastic cell type 
that may be manipulated to treat scars in humans.
MOLeCULAR BiOLOGY OF wOUND 
HeALiNG
Transforming growth factor-beta/Smad signaling has a pivotal 
role in scar-mediated healing. Both TGF-β1 and TGF-β2 enhance 
scarring, i.e., promote fibrosis, whereas TGF-β3 reduces scarring; 
they act through binding to dimeric TGF-β receptor complexes 
(5, 37, 38). Upon activation, this receptor complex phosphoryl-
ates Smad2 and Smad3 proteins, which subsequently form 
dimers with Smad4 that are able to translocate to nucleus and act 
as a transcription factor that triggers target gene transcription 
including collagens I and III (39). TGF-β1 and TGF-β2 activate 
this dimeric receptor complex and thereby downstream Smad 
signaling, whereas TGF-β3 is a receptor antagonist that inhibits 
signal transduction (20, 40). Another Smad protein, Smad7, is 
thought to prevent Smad2/3-receptor interaction and subsequent 
phosphorylation that makes Smad7 as the negative feedback 
regulator of this profibrotic signal pathway. Inducing Smad 7 may 
be promising way to inhibit fibrosis and prevent HS formation 
(41). Not only that TGF-β influences collagen production directly 
through Smad signaling but also induces Smad 3 to transcribe 
proteins that activate the Wnt pathway that induces scarring 
(37, 42). It has been experimentally shown that targeting TGF-
β/Smad pathway influences fibroblast proliferation and ECM 
deposition in HS (40, 43–45).
The local healing process is also influenced by systemic 
response to injury whereby increases in Th2 and possibly Th3 
response cytokines such as IL-2, IL-4, IL-10, and TGF-β are 
found in the circulating lymphocytes in fibrotic conditions (46). 
Among the other momentous mediators of scarring, there are 
proinflammatory cytokines IL-6 and IL-8 that enhance scarring, 
and anti-inflammatory cytokine IL-10 that has the opposite 
effect (47).
We can say that the key to controlled scarring is a balance 
between proliferative processes in proliferative phase and deg-
radation and remodeling processes in the early stage of matura-
tion. Thus, the imbalance between proinflammatory, profibrotic 
growth factors such as TGF-β1 and 2 on one side, and antifibrotic 
factors such as TGF-β3 and MMPs on the other side, results in 
overabundant wound ECM or the formation of a HS. Under 
certain conditions, primarily due to imbalance of synthesis and 
degradation of collagen, normal scar is replaced by pathological 
fibrous tissue with decreased or absent cutaneous fat and hair 
follicles, containing the same ECM molecules as the tissue they 
replace, but in different ratios; increased production of collagen 
type I and III, fibronectin, and laminin, and decreased expression 
of the hyaluronic acid and decorin (7, 47, 48).
HSs veRSUS KeLOiDS
Hypertrophic scars mostly develop within 1–3 months after deep 
skin injury, surgical procedure or burns, in contrast with keloids 
that may occur up to 12 months after injury or even develop spon-
taneously (49). Many factors such as age, genetic factors, race, 
hormone levels, and immunologic responses of the individuals 
appear to play a role (50–52). Not least important, are the type of 
injury, wound size and depth, anatomic region, and mechanical 
tension on the wound (20). Ogawa and Akaishi (51) proposed 
that all of this mentioned risk factors promote pathological scar 
formation by inducing endothelial dysfunction (i.e., vascular 
hyperpermeability) that prolongs and intensifies inflammation, 
thereby leading to fibroblast dysfunction. The first challenge 
when dealing with pathological scarring in daily clinical practice 
is a classification of a scar. Scars can be classified as mature, 
immature, linear hypertrophic, widespread hypertrophic, minor 
and major keloid (53). The diagnosis is usually clinical based 
upon scar appearance, etiology, and growth pattern. Based on 
current guidelines (54), immature scars are morphologically red 
and raised, are often associated with slight pain and pruritus, 
and evolve into mature scars that are pale, soft, narrow, and flat. 
Linear HSs are those scars that we use as a model of HS type with 
all of their typical characteristics described in Table 1. Extensive 
HSs present with irregular, highly erythematous surface and 
have hardened cord-like appearance. They are usually caused by 
thermal or chemical burns and lead to functional impairment due 
to contractures. The terms HS and keloid are often used inconsist-
ently and interchangeably. Although there are clinical similarities 
FiGURe 1 | Clinical appearance of hypertrophic scar (HS) and keloid. 
(A) HSs on upper back that developed after excision of dermal nevi. 
(B) Close-up of HSs. (C) Chest of patient showing keloid developed 
spontaneously. (D) Close-up of keloid.
TABLe 1 | Differences in HSs and keloids.
HSs Keloids
Frequent incidence Rare incidence
Posttraumatic Posttraumatic or spontaneous
Develop soon after surgery May not begin for many months
Usually subside with time Rarely subside with time
Remain within the wound boundaries Spread outside the wound boundaries
No predominant anatomical site but 
often occur when skin creases are at 
right angle or when scars cross joints
Predominant anatomical sites (chest, 
shoulders, upper back, earlobes, 
posterior neck, knees)
Pruritic, rarely painful Pruritic, painful
Less association with phototype More common in darker skin types
Genetic predisposition Less genetic predisposition
Improve with appropriate surgery, low 
recurrence rate
Often worsened by surgery, high 
recurrence rate
Increase collagen synthesis; 7 times 
higher than normal
Increase collagen synthesis; 20 times 
higher than normal
Collagen type I < III Collagen type III < I
Fine collagen fibers organized into 
nodules, predominantly parallel
Large, thick collagen fibers, closely 
packed random to epidermis
Flatter collagen fibers in wavy pattern Fibers lie haphazardly
High collagen cross-link Collagen cross-link twice higher than 
in HS
Myofibroblasts that express α-SMA Absence of myofibroblasts
Fibroblasts: ↑cell number, ↑↑proliferation, 
↓↓apoptosis, ↑↑collagen I
↑↑proliferation, ↑↑collagen I
↑↑TGF-β1, ↑TGF-β2, ↓↓TGF-β3 ↑↑TGF-β1, ↑↑TGF-β2, ↓↓TGF-β3
↑, increase; ↓, decrease; SMA, smooth muscle actin; TGF-β, transforming growth 
factor-beta; HSs, hypertrophic scars.
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between two of them, there are many pathological and bio-
chemical differences that suggest that these entities are distinctive 
(55, 56). HSs are characterized as raised, pink or red scars, some-
times pruritic and painful, within the margins of the original 
wound (Figures 1A,B), that develop soon after surgery and usu-
ally subside with time as opposed to keloids (Figures 1C,D) that 
spread out of the margins of the wound, may develop months after 
the trauma, and continue to evolve over time without regression 
(49, 57). HSs and keloids are also distinguishable based on their 
histologic characteristics. HSs contain primarily type III col-
lagen bundles that are oriented parallel to the epidermal surface 
arranged in a wavy pattern with abundant nodules containing 
myofibroblasts expressing α-SMA and large extracellular collagen 
filaments. In contrast, keloid tissue is composed of disorganized 
type I and III thick, eosinophilic collagen bundles that appear 
randomly oriented to the epithelial surface with no nodules 
or excess myofibroblasts (9, 56, 58, 59). To note is that HSs go 
through a remodeling phase, while keloids do not enter this final 
wound healing phase. Remodeling happens due to the presence 
of myofibroblasts in HSs that account for various processes dur-
ing this phase and contraction of the wound. HS myofibroblasts 
are less responsive to apoptotic signals and produce more ECM 
components especially type I collagen, whose synthesis is seven 
times higher than normal (56). Treatment of HS is demanding, 
often painful, enduring, and mostly unsatisfactory (3). Due to 
the similar underlying pathophysiology, HSs and keloids may 
respond to the same treatment modalities. However, HSs are often 
more responsive and less prone to recurrence, which makes them 
therapeutically less challenging. To date, multiple invasive and 
non-invasive therapies have been used and proposed, but none of 
these has been adequately evaluated in high-quality studies (60). 
Management of HS has transitioned from invasive methods to 
intralesional and topical therapies that act at a cellular level (61).
PReveNTiON iS THe KeY
The most significant segment of an approach to hypertrophic 
scarring is its prevention. Before an elective surgery doctors 
should be informed if their patients have had previous problems 
with scarring. When performing surgery, incisions should fol-
low Langer’s lines that correspond to the natural orientation of 
collagen fibers in the dermis and are parallel to the direction 
of the underlying muscle fibers (62). Incisions made parallel to 
Langer’s lines are known to heal better and produce less scarring 
than those that cut across (63). Also, it is important that all the 
incisions are closed with minimal tension that they do not cross 
joint spaces and that midchest incisions are avoided whenever 
possible (49). For the non-surgical wounds following trauma, 
it is crucial to debride contaminated ones and remove foreign 
bodies to minimize the inflammatory response; also, to promote 
adequate wound management with regular dressing changes 
to provide wound coverage and moist healing (57, 64). All the 
predisposed individuals presenting with any inflammatory skin 
problems as acne or deeper skin infections should be treated cor-
respondingly to minimize inflammation (65). If we cannot avoid 
surgery in patients at a high risk of HS, immediate silicone-based 
products such as gels or sheeting with or without corticosteroid 
injections should be administered. Silicone sheeting is considered 
as the internationally recommended first-line option of scar 
TABLe 2 | Treatment options for hypertrophic scars.
Therapeutic modality 
(application)
Mechanism of action Advantages Disadvantages Comment Reference
Topical agents
Silicone gel
Silicone sheet
Optimal occlusion and hydration of the 
stratum corneum; ↓TEWL, subsequent 
↓cytokine-mediated signaling from 
keratinocytes to dermal fibroblasts. 
Gentle reduction of tension. Static 
electricity
Easy to use, 
can be applied 
at home
Non-invasive, 
safe, tolerated 
by children
Multiple 
formulations 
and formats 
available
Sheets need to be 
washed daily. Risk 
of infection
6–12 months 
constant wear to 
achieve optimum 
results. Expensive
Should be avoided on open wounds
Gel preferred over sheets on visible areas and 
in hot climates
For prevention of HS; treatment can be 
considered as additional therapy in active HS
Poor study design
(66, 81–83)
Onion extract creams Anti-inflammatory effect, bactericidal, 
and inhibit fibroblast proliferation
Flavonoids (quercetin and kaempferol) 
in onion extract play the main role 
in reducing scar formation through 
inhibition of fibroblast proliferation
Induction of MMP-1
Inhibition of TGF-β1 and -β2 and SMAD 
proteins
Improve color, stiffness, and irregularity 
of the scar
Well-tolerated 
preventative 
treatment
Need for early 
initiation
Onion extract therapy should be used 
in combination with an occlusive silicon 
dressing to achieve a satisfying decrease in 
scar thickness. Now available in form of an 
occlusive patch that has dual effect
(84–87)
Imiquimod 5% 
cream (alternate 
night applications for 
2 months after surgery)
↓TNF-α, INF-α, IL-1, IL-4, IL-5, IL-6, 
IL-8, IL-12, alters the expression of 
markers for apoptosis; improved scar 
quality
Minimal 
recurrence
May cause 
hyperpigmentation, 
irritation
Resting period from the treatments usually 
needed
(88, 89)
intralesional injections
Corticosteroid 
injections; TAC 
(10–40 mg/mL into 
papillary dermis every 
2–4 weeks until scar is 
flattened)
Vasoconstrictive, anti-inflammatory, 
immunosuppressive effect. Inhibition of 
keratinocyte and fibroblast proliferation, 
glycosaminoglycan synthesis. ↓MMPs 
inhibitors
Inhibit the 
formation of 
HS. Reduce 
pain and 
pruritus
Multiple injections 
administered 
by a clinician. 
Discomfort, painful. 
Skin atrophy, 
telangiectasia, 
hypopigmentation
Monotherapy or in combination with two 15-s 
cryotherapy cycles prior to application to 
facilitate the injection through the development 
of edema, to reduce the pain and improve 
the result. Clinical benefit of adding 5-FU. 
TAC treatment can be performed on the day 
of surgery to prevent the formation of HS in 
patients at risk
(90–92)
5-FU 50 mg/mL
Weekly intervals, 2- or 
4-week intervals; 3–6 
injections
TAC:5-FU 4:45 mg/mL 
(1:9); 10:37.5 (1:3)
Cell proliferation inhibition, ↑ fibroblast 
apoptosis, collagen-1 suppression, 
MMP-2 induction
No systemic 
side effects
Pain, purpura, 
burning sensation, 
transient 
hyperpigmentation
Risk of ulcerations 
in dark-skinned 
patients
Alone or with corticosteroids (more effective 
and less painful); combination of TAC (40 mg/
mL) and 5-FU (50 mg/mL) (1:3) injected 
intralesionally once weekly for 2 months—
superior to exclusive weekly injection of TAC 
40 mg/mL
The addition of the pulsed-dye laser treatments 
is to be most effective
Not recommended during pregnancy, bone 
marrow suppression, anemia, etc. At the start 
of treatment as well as after four injections a 
blood count should be done
(93–95)
Interferon therapy (INF-
α, β, γ)
INF-α2b—3 times 
weekly
INF-γ—intralesionally 
once per week up to 
a dosage of 0.05 mg 
for 10 weeks or 
0.01–0.1 mg 3 times a 
week/3 week
↑Collagen breakdown, ↓TGF-β (Smad7 
pathway), ↓ECM production, ↓ collagen 
I and III synthesis
No serious 
toxic effects
Dermal cream 
containing 
liposome-
encapsulated 
IFN-α2b
Painful when 
administered 
intralesionally. 
Flu-like symptoms. 
Expensive
Concept of the early topical use of this 
antifibrogenic agent for the treatment of dermal 
fibroproliferative disorders
(96, 97)
(Continued)
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Therapeutic modality 
(application)
Mechanism of action Advantages Disadvantages Comment Reference
Bleomycin [intralesional 
multiple injections 
0.1 mL (1.5 IU/mL) at 
a max dose of 6 mL, 
2–6 sessions within a 
month]
Induces apoptosis, ↓TGF-β1—↓ 
collagen synthesis
↓Height, pliability as well as reduction in 
erythema, pruritus, and pain
Easy to 
administer, 
cheap, high 
regression 
rate, minimum 
complication 
and recurrence
Sporadically, 
development of 
depigmentation 
and dermal 
atrophy has been 
noted. Systemic 
toxic effects 
of intralesional 
injections appear to 
be rare
Considerable success. Due to its toxicity, 
clinicians are encouraged to be aware of 
associated potential problems
Larger scale prospective studies needed
(98–100)
Verapamil (intralesional 
2.5 mg/mL)
Stimulates procollagenase synthesis—
↓collagen synthesis, ↑collagen 
breakdown, ↓scar elevation, vascularity, 
pliability
Low cost, 
fewer adverse 
effects
Monotherapy or as adjuvant therapy after 
excision with or without silicone
(101, 102)
Botulinum toxin A
Intralesional injections 
(2.5 U/mL at 1-month 
intervals) for 3 months
4–7 days before the 
surgery
↓Erythema, itching sensation, and 
pliability
Chemoimmobilization—temporary 
muscular paralysis, ↓tension vectors 
on wound edges, enhances scarring of 
facial wounds. ↓CTGF, ↓TGF-α1
Acceptable for 
both doctors 
and patients
Improvement 
and the rate 
of therapeutic 
satisfaction is 
very high
Expensive Beneficial for use in young patients for wounds 
without tissue loss, lying perpendicular to the 
reduced tension lines of the skin of the face
Larger, randomized, control studies are 
warranted
(103–105)
TGF-β and isomers 
avotermin (hrTGFβ-3) 
(50–500 ng/100 μg 
per linear centimeter 
of wound margin given 
once)
Significant improvement in scar 
appearance
Safe and 
tolerable
Prevention or reduction of scarring following 
surgery. Ongoing clinical trials
(106–108)
Mannose-6-phosphate Reduction of fibrosis by inhibiting  
TGF-β1 and 2 activation
Safe and 
tolerable
Clinical trial
Other current therapeutic options
Compression therapy
Elastic bandages or 
pressure garments 
(20–40 mmHg)
Reduction in scar thickness
MMP-9 activation; prostanglandin E2↑, 
subsequent ↑collagenases. Pressure-
induced hypoxic effects leading to 
collagen and fibroblast degeneration
Non-invasive. 
Can be applied 
at home
Recommended 
for special 
locations  
(e.g., on the 
ear)
Expensive 
(custom made). 
Poor compliance 
(cause discomfort; 
6–24 months 
constant wear to 
achieve optimum 
results). Sweating 
and swelling of the 
limbs; dermatitis, 
pressure erosions, 
and ulcerations can 
develop
Treatment of postburn scars and scars in 
children. Applied when wound is closed. Can 
be used in combination with silicones. The 
beneficial effects remain unproven
(109–113)
Cryotherapy (monthly 
sessions)
Induce vascular damage that may lead 
to anoxia and ultimately tissue necrosis
↓Scar volume, hardness, elevation, 
erythema
Easy to 
perform, low 
cost
Hypopigmentation, 
pain, moderate 
atrophy, protracted 
healing time
Useful on small lesions. Easy to perform. New 
intralesional cryoneedles have shown ↑ efficacy
(95, 114)
Surgery Z- or W-plasty, 
grafts, or local skin 
flaps
Interrupt the circle between scar tension 
and ensuing further thickening of the 
scar due to permanently stimulated 
ECM production
Invasive. Risk of 
recurrence
Z-plasty option for burns. Immediate 
postsurgical additional treatment needed to 
prevent regrowth
First-line treatment if disabling scar 
contractures are present. Surgical therapy of 
HS without tension and without contractures, 
present less than 1 year, is not recommended
(115)
(Continued)
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Therapeutic modality 
(application)
Mechanism of action Advantages Disadvantages Comment Reference
Laser procedures
Ablative lasers (CO2, 
Er:YAG)
Induction of capillary  
destruction—generates  
hypoxemia—alters local collagen 
production. ↑MMPs
Improvement of pigmentation, 
vascularity, pliability, and scar height
Reach greater 
depths than 
a pulsed-dye 
laser
Mild side effects 
that include a 
prickling sensation 
during treatment 
and post-treatment 
erythema
Erosions, weeping, 
and crusting can 
occur
For inactive HS with height differences, bridge 
or contracture formation. CO2 shows superior 
effectiveness. Fractional CO2 is option in 
postburn HS
(116)
Non-ablative lasers; 
pulsed-dye laser 
585/595 nm
Induction of selective capillary 
destruction—generates  
hypoxemia—alters local collagen 
production. ↑MMPs
Minimal 
side effects, 
purpura usually 
persisting for 
7–14 days
Expensive. 
Specialist 
referral needed. 
Vascular-specific
Excellent first-line treatment, preventive 
strategy for HS, reduce erythema primarily
(98, 117, 
118)
Gold standard: 
application on the day 
of suture removal, 
44.5 J/cm2 about 
1.5–2 ms (every 
3–4 weeks)
Reducing erythema, pruritus, pliability, 
improving skin texture
Depending 
on the energy 
density 
employed, 
vesicles and 
crusts may 
occur
Do not appear to be adequate for thick HS
↑, increase; ↓, decrease; TEWL, transepidermal water loss; ECM, extracellular matrix; MMP, matrix metalloproteinase; HS, hypertrophic scar; CTGF, connective tissue growth factor; 
IL, interleukin; 5-FU, 5-fluorouracil; TAC, triamcinolone acetonide; TGF-β, transforming growth factor-beta.
TABLe 2 | Continued
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management, which should be used after the wound has fully 
epithelialized (66). They should be applied for 12–24 h/day with 
daily washing for at least 2 months up to 1–2 years (54). Silicone 
gel is often preferred to sheeting from the perspective of ease of 
application and patient compliance especially when applied on 
the face, mobile areas, and in patients living in humid climates 
due to sheeting dislodgment. Silicone gel has been shown not 
to be inferior to sheeting in improving objective and subjective 
characteristics of scars, but it is superior in the ease of use (67). 
However, for extensive hypertrophic burn scars pressure gar-
ments still represent the first-line prophylactic therapy (68). The 
type of preventive scar measure that would be applied to a patient 
depends on the individual’s risk factors and his/her esthetic con-
cerns. After trauma, in patients with moderate risk of scarring it 
is advised to apply silicone gels or dressings as preferred therapy, 
with topical products containing onion extracts or hypoallergenic 
adhesive tape for a few weeks after surgery as acceptable alterna-
tives (69). In low-risk patients, we should just monitor wounds 
and prescribe silicone sheeting products for worried individuals 
(70). Other general measures to prevent HS formation include 
compression therapy, the use of moisturizers, manual massage, 
and strict UV photoprotection measures during scar formation 
and maturation phase to avoid hyperpigmentation (71, 72). As 
a rule, scars should be reevaluated 4–8  weeks after surgery to 
determine further management.
SCAR evALUATiON
If eventually scar forms, regardless of whether or not prophylactic 
measures were applied, it should be evaluated. When assessing 
scars, their size, color, contour, height (thickness), surface area, 
surface texture, pliability, location, and subjective symptoms such 
as itching and pain, and also patient’s perception should be taken 
into account. It has been indicated that this subjective component 
of the patient’s view of the scar is as important as objective aspect 
and it may be very influential in determining the patient’s quality 
of life (73, 74). Assessment of the scars is a frequent topic of dis-
cussion among clinicians because there is no generally accepted 
evaluation tool, although various ones have been proposed 
(75–77). None of these, however, seem suitable as a stand-alone 
tool, suggesting that combination of objective imaging tools and 
scar scales and questionnaires may be justified to achieve compre-
hensive documentation in everyday clinical practice (78).
CURReNT APPROACH TO HS 
MANAGeMeNT
When dealing with future scar reduction modalities, it is of great 
importance for clinicians to not only discuss with patients their 
concerns, needs, and expectations but also to educate them about 
possible treatment options and their outcomes. The approach 
to treatment and its goals should be set for the individual 
patient based upon scar evaluation, patients’s characteristics, 
and expectations in order to reduce the scar volume, minimize 
subjective symptoms, i.e., pain and pruritus, and to improve 
function and esthetic appearance. As we have mentioned earlier, 
HSs are characterized by their ability to potentially regress over 
time. However, this maturation process is slow. So, the goal of 
the treatment is to stimulate this process to improve objective 
and subjective symptoms. According to updated international 
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clinical recommendations on scar management (54) and others 
that adopted them (70), when treating linear or small HS resulting 
from trauma or surgery, silicone gel sheeting and topical onion 
extracts are considered as the first-line therapy. If there is no 
improvement within a month, we can start second-line therapy 
that is intralesional corticosteroid injections—triamcinolone 
acetonide 10–40 mg/mL with or without cryosurgery at monthly 
intervals for 3–4 months. Second-line therapy also includes laser 
therapy (pulsed-dye laser or fractional laser) and surgical excision 
in combination with postoperative silicone sheeting or postopera-
tive intralesional corticosteroid/5-fluorouracil (5-FU) injections 
(79). Corticosteroids suppress healing and abnormal scarring 
by three mechanisms: vasoconstriction, anti-inflammatory and 
immunosuppressive effect, and inhibition of keratinocyte and 
fibroblast proliferation (80). When facing extensive HSs as are the 
postburn ones, of great importance is acute treatment at special-
ized burn centers where debridement and possible skin grafting are 
performed. Afterward, first-line therapy, as in linear HSs, includes 
silicone sheeting or gel and topical onion extracts. First-line also 
includes pressure garments that are also the first-line prophylactic 
therapy measure for postburn scars. Current international guide-
lines recommend ablative fractional laser, CO2 laser, as promising 
second-line therapy for this extensive HSs but also for inactive, 
linear HSs. The abovementioned commonly used and innovative 
scar-reducing modalities are presented in detail in Table 2.
CONCLUSiON
Scarring and its accompanying esthetic, functional, and psy-
chological sequelae still pose major challenges. To date, there is 
no satisfactory prevention or treatment option for HS, which is 
mostly due to not completely comprehending the mechanisms 
underlying their formation. A predominant role in hypertrophic 
scarring prevention and treatment still maintain silicone sheeting 
or gel. The efficacy and safety of this gold-standard, non-invasive 
therapy has been demonstrated in many clinical studies, but to 
date, exact mechanisms by which they improve HS are yet to be 
fully agreed upon. Second most validated and more specialized 
scar treatment is intralesional corticosteroid injections, especially 
in combination with other therapeutic modalities like 5-FU, 
which augment the result and reduce the side effects of corti-
costeroids. Current therapeutic approaches with their empirical 
effects are unreliable and unpredictable. Therefore, there is an 
unmet need for an effective, targeted therapy and prevention, 
which would be based on an action or a modulation of a specific 
factor with clarified mechanism of action that has a beneficial 
effect on wound healing. As the ECM is involved in cellular and 
extracellular events that lead to pathological scarring, targeting 
its components mostly by regulating BMPs may throw up new 
therapeutic approach for reduction or prevention of pathological 
scarring or HSs with functionally and cosmetically acceptable 
outcome.
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